At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 43 enrolled
Drug / intervention
secukinumab 150mg +1 moredrug
Likely dose
secukinumab 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Double Dummy, Multicenter Study to Assess the Safety, Tolerability and Long-term Efficacy of Intravenous (10mg/kg) and Subcutaneous (300mg) Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Who Are Partial Responders to Secukinumab
In Brief
A Phase 3 clinical trial evaluating secukinumab 150mg and secukinumab 10mg/kg i.v. regimen for Plaque-type Psoriasis. Completed, enrolled 43 participants across 27 sites in 8 countries.
Detailed Summary
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque-type Psoriasis
CountriesAustria, Canada, France, Germany, India, Japan, Slovakia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartDec 2011
Primary CompletionApr 2013
TodayJul 2026
First PostedAug 9, 2011
Enrollment StartDec 1, 2011
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.9 years ago
Interventions
secukinumab 150mgdrug
secukinumab 150mg (2 injections per dose)
secukinumab 10mg/kg i.v. regimendrug
secukinumab 10mg/kg i.v. regimen